Literature DB >> 15792607

Severe comorbidity negatively influences prognosis in patients with oral and oropharyngeal cancer after surgical treatment with microvascular reconstruction.

Pepijn A Borggreven1, Dirk J Kuik, Johannes A Langendijk, Patricia Doornaert, Remco de Bree, C René Leemans.   

Abstract

The aim of the study was to investigate the possible impact of comorbidity on survival of patients undergoing composite resection and microvascular reconstruction for oral/oropharyngeal cancer. Patient, tumour and treatment data were recorded. Comorbidity was graded by the Adult Comorbidity Evaluation (ACE-27) test. Survival and statistics were calculated. Comorbidity score ACE-27 grade 2 was present in 47% of patients, for ACE-27 grade 3 this was 13%. The median follow-up was 50 (3-87) months. Thirty-eight patients died, 32 developed a recurrence. Comorbidity score ACE-27 grade 3 turned out to be a clear predictor for overall survival (p<0.05). For ACE-27 grade 3 (n=13) 5-years survival was 29%, for ACE-27 grade 2 (n=87) this was 64%. No multivariate influences on the effects of comorbidity were found. Improved knowledge of the effect of comorbidity on survival may lead to better patient selection and counselling for major surgery and microvascular reconstruction.

Entities:  

Mesh:

Year:  2005        PMID: 15792607     DOI: 10.1016/j.oraloncology.2004.08.012

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  8 in total

1.  Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer.

Authors:  Xerxes Pundole; Natalia V Zamora; Harish Siddhanamatha; Heather Lin; Jean Tayar; Leung Cheuk Hong; Liang Li; Maria E Suarez-Almazor
Journal:  Clin Rheumatol       Date:  2019-12-18       Impact factor: 2.980

2.  Treatment selection in oropharyngeal cancer: a surveillance, epidemiology, and end results (SEER) patterns of care analysis.

Authors:  Nitin A Pagedar; Catherine Chioreso; Jennifer A Schlichting; Charles F Lynch; Mary E Charlton
Journal:  Cancer Causes Control       Date:  2017-08-16       Impact factor: 2.506

3.  Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancer.

Authors:  Robert B Hines; Chandrakumar Shanmugam; John W Waterbor; Gerald McGwin; Ellen Funkhouser; Christopher S Coffey; James Posey; Upender Manne
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

4.  Multilevel Associations Between Patient- and Hospital-Level Factors and In-Hospital Mortality Among Hospitalized Patients With Head and Neck Cancer.

Authors:  Eric Adjei Boakye; Nosayaba Osazuwa-Peters; Betty Chen; Miao Cai; Betelihem B Tobo; Sai D Challapalli; Paula Buchanan; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-05-01       Impact factor: 6.223

5.  Comorbidity, human papillomavirus infection and head and neck cancer survival in an ethnically diverse population.

Authors:  Ashish A Ankola; Richard V Smith; Robert D Burk; Michael B Prystowsky; Catherine Sarta; Nicolas F Schlecht
Journal:  Oral Oncol       Date:  2013-07-25       Impact factor: 5.337

6.  Free flap reconstruction for head and neck cancer can be safely performed in both young and elderly patients after careful patient selection.

Authors:  Thomas T A Peters; Sophie F Post; Boukje A C van Dijk; Jan L N Roodenburg; Bernard F A M van der Laan; Paul M N Werker; Gyorgy B Halmos
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-09-13       Impact factor: 2.503

7.  Quality of life and functional status in patients with cancer of the oral cavity and oropharynx: pretreatment values of a prospective study.

Authors:  Pepijn A Borggreven; Irma M Verdonck-de Leeuw; Martin J Muller; Milou L C H Heiligers; Remco de Bree; Neil K Aaronson; C René Leemans
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-02-02       Impact factor: 2.503

Review 8.  Salvage surgery in post-chemoradiation laryngeal and hypopharyngeal carcinoma: outcome and review.

Authors:  L Putten; R Bree; P A Doornaert; J Buter; S E J Eerenstein; D H F Rietveld; D J Kuik; C R Leemans
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-06       Impact factor: 2.124

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.